- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Samjin Pharm (005500)
The Samjin Pharm share price today is 22,400, view KS 005500 stock exchange data. Track the latest Samjin Pharm share price with real-time updates on 005500 stock performance including market cap, day range, 52-week range and dividend yield. Access 005500 charts, earnings dates and analyst estimates to support your investment decisions.
Seoul
Currency in KRW
22,400
-100(-0.44%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
22,000
23,100
52 wk Range
16,990
25,900
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
22,00023,100
52 wk Range
16,99025,900
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.56%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.56%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
005500 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
26,000
Upside
+16.07%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock generally trades with high price volatility
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 26,000
(+16.07% Upside)
Earnings
Latest Release
15-05-2026
EPS / Forecast
-- / --
Revenue / Forecast
68.1B / --
Compare 005500 to Peers and Sector
Metrics to compare | 005500 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship005500PeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | 5.6x | −0.5x | |
PEG Ratio | 0.00 | 0.01 | 0.00 | |
Price/Book | 0.0x | 1.1x | 2.6x | |
Price / LTM Sales | 0.0x | 0.6x | 3.1x | |
Upside (Analyst Target) | 0.0% | 49.0% | 53.0% | |
Fair Value Upside | Unlock | 9.8% | 6.3% | Unlock |
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clinical trial to treat macular degeneration; and SJP1604, which is in Phase I clinical trial for cancer; SJP1901 and SJP1902 for cancer treatment; SJP 1801 to treat Alzheimer’s and Parkinson’s disease; SJP006, an anti-viral product; and SJP003 for treatment of diabetes. In addition, the company's preclinical product is SJP1602 for the treatment of cancer. Samjin Pharmaceuticals Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Samjin Pharm (005500) Share Price Today?
The Samjin Pharm share price today is 22,400.
What is the current Samjin Pharm (005500) share price and day range?
As of 23-05-2026, the Samjin Pharm share price is 22,400, with a previous close of 22,500. The share price has ranged from 22,000 to 23,100 today, while the 52-week range spans from 16,990 to 25,900.
What Is the Samjin Pharm Market Cap?
As of today, Samjin Pharm market cap is 274.57B.
Does Samjin Pharm Pay Dividends? What's The Current Dividend Yield?
The Samjin Pharm dividend yield is 3.56%.
What Is the Samjin Pharm (005500) Share Price Target?
The average 12-month share price target for Samjin Pharm is 26,000, with a high estimate of 26000 and a low estimate of 26000. 1 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +16.07% Upside potential.
What Is Samjin Pharm's Earnings Per Share (TTM)?
The Samjin Pharm EPS (TTM) is 1,728.
When Is the Next Samjin Pharm Earnings Date?
Samjin Pharm will release its next earnings report on 18-08-2026.
From a Technical Analysis Perspective, Is 005500 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Samjin Pharm Trade On?
Samjin Pharm is listed and trades on the Seoul Stock Exchange.
What Is the Stock Symbol for Samjin Pharm?
The stock symbol for Samjin Pharm is "005500."
How Many Times Has Samjin Pharm Stock Split?
Samjin Pharm has split 6 times.
How Many Employees Does Samjin Pharm Have?
Samjin Pharm has 586 employees.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.